Genetic variants of thiopurine and folate metabolic pathways determine 6-MP-mediated hematological toxicity in childhood ALL

Pharmacogenomics

Volumn 13, Issue 9, 2012, Pages 1001-1008

  Dorababu, Patchva ^a   Naushad, Shaik Mohammad ^a   Linga, Vijay Gandhi ^a   Gundeti, Sadashivudu ^a   Nagesh, Narayana ^b   Kutala, Vijay Kumar ^a   Reddanna, Pallu ^c   Digumarti, Raghunadharao ^a  

^a NIZAM'S INSTITUTE OF MEDICAL SCIENCES   (India)

^b CENTRE FOR CELLULAR AND MOLECULAR BIOLOGY   (India)

^c UNIVERSITY OF HYDERABAD   (India)

Author keywords

6 mercaptopurine; childhood acute lymphoblastic leukemia; folate metabolism; haplotype; pharmacogenetics; S adenosyl methionine; thiopurine methyltransferase

Indexed keywords

FOLIC ACID; GENOMIC DNA; MERCAPTOPURINE; METHOTREXATE;

3' UNTRANSLATED REGION; 5' UNTRANSLATED REGION; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AMPLIFIED FRAGMENT LENGTH POLYMORPHISM; ARTICLE; BLOOD TOXICITY; CHILD; CHILDHOOD LEUKEMIA; CONTROLLED STUDY; DNA ISOLATION; DRUG DOSE TITRATION; FEMALE; FOLATE METABOLISM; GENE INTERACTION; GENETIC POLYMORPHISM; GENETIC SCREENING; GENETIC VARIABILITY; HAPLOTYPE; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; NUCLEIC ACID METABOLISM; POLYMERASE CHAIN REACTION; PRESCHOOL CHILD; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SCHOOL CHILD;

6-MERCAPTOPURINE; ADOLESCENT; BIOMARKERS, PHARMACOLOGICAL; CHILD; CHILD, PRESCHOOL; FEMALE; FOLIC ACID; GENETIC ASSOCIATION STUDIES; GLUTAMATE CARBOXYPEPTIDASE II; HAPLOTYPES; HUMANS; MALE; METABOLIC NETWORKS AND PATHWAYS; METHOTREXATE; METHYLTRANSFERASES; POLYMORPHISM, SINGLE NUCLEOTIDE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PYROPHOSPHATASES;

EID: 84864404408     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.12.70     Document Type: Article

References (21)

1. Krynetski EY, Evans WE. Pharmacogenetics of cancer therapy: getting personal. Am. J. Hum. Genet. 63(1), 11-16 (1998).
2. McLeod HL, Krynetski EY, Relling MV, Evans WE. Genetic polymorphism of thiopurine methyltransferase and its clinical relevance for childhood acute lymphoblastic leukemia. Leukemia 14(4), 567-572 (2000).
3. Lennard L, Lilleyman JS, Van LJ, Weinshilboum RM. Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia. Lancet 336(8709), 225-229 (1990).
4. Yates CR, Krynetski EY, Loennechen T et al. Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. Ann. Intern. Med. 126(8), 608-614 (1997).
5. Krynetski EY, Krynetskaia NF, Yanishevski Y, Evans WE. Methylation of mercaptopurine, thioguanine, and their nucleotide metabolites by heterologously expressed human thiopurine S-methyltransferase. Mol. Pharmacol. 47(6), 1141-1147 (1995).
6. Loennechen T, Yates CR, Fessing MY, Relling MV, Krynetski EY, Evans WE. Isolation of a human thiopurine S-methyltransferase (TPMT) complementary DNA with a single nucleotide transition A719G (TPMT*3C) and its association with loss of TPMT protein and catalytic activity in humans. Clin. Pharmacol. Ther. 64(1), 46-51 (1998).
7. Tai HL, Krynetski EY, Yates CR et al. Thiopurine S-methyltransferase deficiency: two nucleotide transitions define the most prevalent mutant allele associated with loss of catalytic activity in Caucasians. Am. J. Hum. Genet. 58(4), 694-702 (1996).
8. Otterness D, Szumlanski C, Lennard L et al. Human thiopurine methyltransferase pharmacogenetics: gene sequence polymorphisms. Clin. Pharmacol. Ther. 62(1), 60-67 (1997).
9. Dorababu P, Nagesh N, Linga VG et al. Epistatic interactions between thiopurine methyltransferase (TPMT) and inosine triphosphate pyrophosphatase (ITPA) variations determine 6-mercaptopurine toxicity in Indian children with acute lymphoblastic leukemia. Eur. J. Clin. Pharmacol. 68(4), 379-387 (2012).
10. Dorababu P, Naushad SM, Kutala VK, Digumarti R. Impact of age, gender and haplotypes of thiopurine methyltransferase (TPMT) and inosine triphosphate pyrophosphatase (ITPA) genes on 6-mercaptopurine toxicity in children with acute lymphoblastic leukemia. Eur. J. Clin. Pharmacol. 68(5), 885-886 (2012).
11. Scheuermann TH, Keeler C, Hodsdon ME. Consequences of binding an S-adenosyl methionine analogue on the structure and dynamics of the thiopurine methyltransferase protein backbone. Biochemistry 43(38), 12198-12209 (2004).
12. Tai HL, Krynetski EY, Schuetz EG, Yanishevski Y, Evans WE. Enhanced proteolysis of thiopurine S-methyltransferase (TPMT) encoded by mutant alleles in humans (TPMT*3A, TPMT*2): mechanisms for the genetic polymorphism of TPMT activity. Proc. Natl Acad. Sci. USA 94(12), 6444-6449 (1997).
13. Zaza G, Cheok M, Yang W et al. Gene expression and thioguanine nucleotide disposition in acute lymphoblastic leukemia after in vivo mercaptopurine treatment. Blood 106(5), 1778-1785 (2005).
14. Karas-Kuzelicki N, Jazbec J, Milek M, Mlinaric-Rascan I. Heterozygosity at the TPMT gene locus, augmented by mutated MTHFR gene, predisposes to 6-MP related toxicities in childhood ALL patients. Leukemia 23(5), 971-974 (2009).
15. Karas-Kuzelicki N, Milek M, Mlinaric-Rascan I. MTHFR and TYMS genotypes influence TPMT activity and its differential modulation in males and females. Clin. Biochem. 43(1-2), 37-42 (2010).
16. Advani S, Pai S, Venzon D et al. Acute lymphoblastic leukemia in India: an analysis of prognostic factors using a single treatment regimen. Ann. Oncol. 10(2), 167-176 (1999).
17. Mohammad NS, Yedluri R, Addepalli P, Gottumukkala SR, Digumarti RR, Kutala VK. Aberrations in one-carbon metabolism induce oxidative DNA damage in sporadic breast cancer. Mol. Cell. Biochem. 349(1-2), 159-167 (2011).
18. Shimasaki N, Mori T, Torii C et al. Influence of MTHFR and RFC1 polymorphisms on toxicities during maintenance chemotherapy for childhood acute lymphoblastic leukemia or lymphoma. J. Pediatr. Hematol. Oncol. 30(5), 347-352 (2008).
19. Arenas M, Simpson G, Lewis CM et al. Genetic variation in the MTHFR gene influences thiopurine methyltransferase activity. Clin. Chem. 51(12), 2371-2374 (2005).
20. Devlin AM, Ling EH, Peerson JM et al. Glutamate carboxypeptidase II: a polymorphism associated with lower levels of serum folate and hyperhomocysteinemia. Hum. Mol. Genet. 9(19), 2837-2844 (2000).
21. Divyya S, Naushad SM, Addlagatta A et al. Paradoxical role of C1561T glutamate carboxypeptidase II (GCPII) genetic polymorphism in altering disease susceptibility. Gene. 497(2), 273-279 (2012).